The ABPI and the PM Society have signed a new deal aimed at aligning the two groups services.
The memorandum of understating is an agreement committing the UK industry group and the PM Society – the pharma marketing and networking firm - to see how they might align activities that benefits them both.
Examples include events, training, content development and surveys designed to identify common issues and facilitate planning to meet arising needs. The deal is not expected to involved any PR duties for the PM Society, or any financial dealings as both organisations as both are not-for-profit.
Stephen Whitehead, chief executive, ABPI says: “The PM Society reaches out to the operational heart of the UK pharmaceutical and life sciences industries and is a natural partner to promote debate and discussion with the people we serve.
“The working groups in market access, NHS partnerships and patient engagement, aligned as they are with many of our strategic imperatives, offer particular potential for joint-working. I hope the MoU can help drive forward these partnerships and ultimately help the pharmaceutical industry serve patients more effectively.”
Chairman of the PM Society Neil Copping, said: “Since we redefined the Society early last year, we have looked to address members’ needs more effectively in the rapidly changing healthcare environment. Aligning strategic and grass roots level activities by joining forces with the ABPI we aim to open new doors and deliver increased value and benefit to both organisations’ membership. Importantly, it will also avoid duplication on initiatives that are relevant industry-wide and might otherwise have been under discussion by both organisations.”
The views expressed in the following comments are not those of PharmaTimes or any connected third party and belong specifically to the individual who made that comment. We accept no liability for the comments made and always advise users to exercise caution.